Could ASPIRIN be the first over the counter treatment for coronavirus? Hospitalized patients already taking the drug daily were 47% less likely to die

[Mary Wilson]

By MARY KEKATOS and VANESSA CHALMERS

PUBLISHED: 15:27 EDT, 26 October 2020 | UPDATED: 13:59 EDT, 27 October 2020

• Covid-19 patients using aspirin were 43% less likely to be admitted to the ICU
• They were also 44% less likely to need ventilators due to their heart medication
• Daily aspirin use also reduced the risk of death by 47%
• Researchers say aspirin could be the first over-the counter drug for Covid-19

Taking aspirin could reduce the risk of hospitalized Covid-19 patients falling severely ill or dying, a new study suggests.

Researchers found a daily low-dose pill could lower the likelihood of being admitted to the ICU or being placed on a ventilator by more than 40 per cent. Additionally, it cut the risk of dying from the infection by nearly half, when compared to people who were not taking the medicine.

University of Maryland School of Medicine (UMSOM) experts say the findings provide 'cautious optimism' of using aspirin to help prevent severe complications caused by Covid-19.

​​​​​​​https://www.dailymail.co.uk/health/...ing-aspirin-daily-47-likely-die-COVID-19.html

 

[Emily]

Another cheap old standby like steroids.

 

[kiwibird]

This is exactly the opposite advice we were given early on. Good to have concrete scientific based evidence of benefits. Well done Dr. Jonathan Chow and team at University of Maryland. Also well done reporters for highlighting the study (and thank you Mary Wilson for finding it for us.)

https://www.dailymail.co.uk/health/...ing-aspirin-daily-47-likely-die-COVID-19.html
'This is a critical finding that needs to be confirmed through a randomized clinical trial,' said study leader Dr Jonathan Chow, assistant professor of anesthesiology at UMSOM.

 

[sharon sanders]

bump this

 

[Vibrant62]

Full study here https://journals.lww.com/anesthesia...n_Use_is_Associated_with_Decreased.95423.aspx

 

[Mary Wilson]

RECOVERY Randomised Evaluation of COVID-19 Therapy

Aspirin to be investigated as a possible treatment for COVID-19 in the RECOVERY trial

6 November 2020

From today, aspirin will be investigated in the world’s largest clinical trial of treatments for patients hospitalised with COVID-19. The Randomised Evaluation of COVid-19 thERapY (RECOVERY) trial is taking place in 176 hospital sites across the UK, and has so far recruited over 16,000 patients.

Patients with COVID-19 are at higher risk of blood clots forming in their blood vessels...

https://www.recoverytrial.net/news/...-treatment-for-covid-19-in-the-recovery-trial

 

[Mary Wilson]

I found this, which contains some interesting information.


RANDOMISED EVALUATION OF COVID-19 THERAPY (RECOVERY)


Background: In early 2020, as this protocol was being developed, there were no approved treatments for COVID-19, a disease induced by the novel coronavirus SARS-CoV-2 that emerged in China in late 2019. The UK New and Emerging Respiratory Virus Threats Advisory Group (NERVTAG) advised that several possible treatments should be evaluated, including Lopinavir-Ritonavir, low-dose corticosteroids, and Hydroxychloroquine (which has now been done). A World Health Organization (WHO) expert group issued broadly similar advice. These groups also advised that other treatments will soon emerge that require evaluation.

Eligibility and randomisation: ...

https://www.recoverytrial.net/files/recovery-protocol-v10-1-2020-11-01.pdf

 

[Mary Wilson]

COVID-19–Associated Coagulopathy and Inflammatory Response: What Do We Know Already and What Are the Knowledge Gaps?

G?rlinger, Klaus MD[SUP]*,†[/SUP]; Dirkmann, Daniel MD, PhD[SUP]*[/SUP]; Gandhi, Ajay MD[SUP]‡[/SUP]; Simioni, Paolo MD, PhD[SUP]?[/SUP]

Anesthesia & Analgesia: November 2020 - Volume 131 - Issue 5 - p 1324-1333
doi: 10.1213/ANE.0000000000005147

Abstract

Patients with coronavirus disease 2019 (COVID-19) frequently experience a coagulopathy associated with a high incidence of thrombotic events leading to poor outcomes. Here, biomarkers of coagulation (such as D-dimer, fibrinogen, platelet count), inflammation (such as interleukin-6), and immunity (such as lymphocyte count) as well as clinical scoring systems (such as sequential organ failure assessment [SOFA], International Society on Thrombosis and Hemostasis disseminated intravascular coagulation [ISTH DIC], and sepsis-induced coagulopathy [SIC] score) can be helpful in predicting clinical course, need for hospital resources (such as intensive care unit [ICU] beds, intubation and ventilator therapy, and extracorporeal membrane oxygenation [ECMO]) and patient’s outcome in patients with COVID-19. However, therapeutic options are actually limited to unspecific supportive therapy. Whether viscoelastic testing can provide additional value in predicting clinical course, need for hospital resources and patient’s outcome or in guiding anticoagulation in COVID-19–associated coagulopathy is still incompletely understood and currently under investigation (eg, in the rotational thromboelastometry analysis and standard coagulation tests in hospitalized patients with COVID-19 [ROHOCO] study). This article summarizes what we know already about COVID-19–associated coagulopathy and—perhaps even more importantly—characterizes important knowledge gaps.

https://journals.lww.com/anesthesia...sociated_Coagulopathy_and_Inflammatory.2.aspx

 

[Emily]

This is a comment from a USA vitamin/herb site, (no link since it is commercial), machine translated from Russian. (They get a lot of Russian customers. They say the old Soviet system is still strong in medicine, and even if they are very low in vitamin D and their doctor wants them on a high dose, they can't get it in Russia yet.)

The consequences of the coronavirus
After my husband had been ill with coronavirus, there were changes in blood viscosity. This is what makes COVID-19 stand out. The doctor explained that the viscosity of the blood increases, which leads to the formation of many microthrombi, mainly in the lungs. Therefore, a daily intake of asperin is obligatory and advised to drink asperin with the whole family. But I don't want to drink chemical asperin for the sake of prevention. [snipped since I don't know if this herb is a substitue for this purpose] I wish you good health.

So it sounds like if there is one patient in a family with COVID, the whole family is encouraged to go on aspirin, perhaps due to the chance of asymptomatic cases. But there are side effects to aspirin, so I can understand her concern about taking it as a preventative if you haven't been sick. Are they seeing blood disorders in people exposed to COVID who have not been ill?